Skip to main content

Advertisement

Table 3 The inter-relationship between clinico-pathological characteristics and lymphatic invasion (LVI D2-40 ) in patients with primary operable invasive ductal breast cancer

From: Immunohistochemical detection improves the prognostic value of lymphatic and blood vessel invasion in primary ductal breast cancer

All patients (n = 360) LVID2–40-ve LVID2–40+ve ( P-value)
n = 233 (65%) n = 127 (35%)
Age (≤50/ >50 years) 69/164 56/71 0.006
Size (≤20/ 21-50/ >50 mm) 129/97/7 56/65/6 0.038
Grade (I / II / III) 156/73/13 56/53/21 <0.001
Involved lymph node (0/1-3/ >3) 153/80 53/74 <0.001
ER status (no/yes) 102/131 69/58 0.056
PR status (no/yes) 118/115 76/51 0.095
HER2 status (no/yes) 193/40 96/31 0.099
Endocrine therapy (no/yes) 168/62 104/19 0.014
Chemotherapy (no/yes) 150/80 59/64 0.002
Tumour recurrence (no/local/distant/both) 199/5/28/1 72/12/39/4 <0.001
Alive/cancer death/non cancer death 141/39/53 48/58/21 0.059
Cancer specific survival (months)a 186(177–194) 134(120–149) <0.001
Node-negative disease (n = 206) n = 153 (74%) n = 53 (26%)  
Age (≤50/ >50 years) 42/111 25/28 0.008
Size (≤20/ 21-50/ >50 mm) 96/55/2 24/27/2 0.019
Grade (I / II / III) 33/53/67 1/20/32 0.002
ER status (no/yes) 32/48 40/34 0.082
PR status (no/yes) 38/42 43/31 0.189
HER2 status (no/yes) 130/23 38/15 0.032
Endocrine therapy (no/yes) 106/46 43/9 0.070
Chemotherapy (no/yes) 111/41 31/21 0.070
Tumour recurrence (no/local/distant/both) 137/4/11/1 33/4/14/2 <0.001
Alive/cancer death/non cancer death 99/18/36 25/17/11 0.266
Cancer specific survival (months)a 198(190–206) 153(131–174) 0.001
Triple-negative patients (n = 120) n = 74(62%) 46(38%)  
Age (≤50/ >50 years) 26/48 24/22 0.064
Size (≤20/ 21-50/ >50 mm) 42/28/4 21/23/2 0.367
Grade (I / II / III) 1/13/60 0/8/38 0.712
Involved lymph node (-ve/+ve) 52/22 18/28 0.001
Endocrine therapy (no/yes) 65/9 42/3 0.336
Chemotherapy (no/yes) 36/38 15/30 0.103
Tumour recurrence (no/local/distant) 64/0/10 24/3/19 <0.001
Alive/cancer death/non cancer death 48/13/13 18/24/4 0.217
Cancer specific survival (months)a 176(161–192) 122(96–147) <0.001
  1. a = Mean (95% CI).